Why the study?
Does sesamol prevent doxorubicin-induced oxidative damage and toxicity in H9c2 cardiomyoblasts?
Population
Doxorubicin-exposed cardiac myoblasts (H9c2 cells)
Comparison
Sesamol (12.5, 25 and 50 μm) vs Doxorubicin exposure without sesamol
Design
Preclinical
Authors
Loading...
Sesamol merits further preclinical testing for doxorubicin cardiotoxicity; leaves open any clinical role.
Does sesamol prevent doxorubicin-induced oxidative damage and toxicity in H9c2 cardiomyoblasts?
Sesamol protects against doxorubicin-induced oxidative damage and apoptosis in H9c2 cardiomyoblasts, suggesting potential utility in mitigating chemotherapy-induced cardiotoxicity.
Nayak et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: